Monographie - Palonosetron hydrochloride

Ultimele actualizari :
28/04/2024

Palonosetron hydrochloride

Formula chimica

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aloxi	Austria, Belgia, Canada, Danemarca, Elvetia, Finlanda, Germania, Grecia, Irlanda, Islanda, Italia, Japonia, Luxemburg, Malaezia, Marea Britanie, Norvegia, Olanda, Polonia, Portugalia, Romania, Spania, SUA, Suedia, Turcia, Ungaria
Chepatron	India
Cinvex	Turcia
Factoket	Mexic
Lotisa	Turcia
Onicit	Chilli, Columbia, Ecuador, Italia, Peru
Palohalt	Chilli, Peru
Paloject	Turcia
Palonosetron	Belgia, Chilli, Ecuador, Elvetia, Franta, Germania, Marea Britanie, Spania
Palostar	India
Palzen	India
Vinaltro	Mexic
Viqet	Mexic
Vonaxi	Turcia

Bibliografie : Palonosetron hydrochloride

	Tip	Publicare
1932	Ziar	Trissel LA, Zhang Y. Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int J Pharm Compound 2004 ; 8,5: 398-403.
1936	Ziar	Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solusions. Ann Pharmacotherapy 2004 ; 38: 1608-1611.
1940	Ziar	Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1950	Ziar	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1955	Ziar	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
1975	Ziar	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.
1976	Ziar	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2009	Ziar	Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2016	Ziar	Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2107	Ziar	Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236.
2179	Ziar	Trusley C, Ben M, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 1: 82-85.
2196	Ziar	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2214	Ziar	Ben M, Trusley C,Kupiec T.C, Trissel L.A. Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 6: 520-524.
2227	Ziar	Trusley C, Ben M, Kupiec TC, Trissel LA. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 2: 156-160.
2228	Ziar	Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173.
2279	Ziar	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2281	Ziar	Ben M, Kupiec T, Trusley C, Trisel LA. Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 5: 460-462.
2286	Ziar	Ben M, Trusley C, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 4: 368-371.
2312	Ziar	Trissel L.A, Trusley C, Kupiec T.C, Ben M. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharm Compound 2009 ; 13, 1: 78-80.
3459	Ziar	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3928	Ziar	Wu G, Yeung S, Chen F. Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride. Int J Pharm Compound 2017 ; 21, 1: 76-82.
3981	Ziar	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166
4062	Ziar	Wu George, Powers Dan, Yeung S, Chen F, Neelon K. Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection. Int J Pharm Compound 2018 ;22,1:76-85
4310	Ziar	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

Mentions Légales